Relative Exchangeable Copper, Exchangeable Copper and Total Copper in the Diagnosis of Wilson Disease
- PMID: 40198317
- PMCID: PMC11977851
- DOI: 10.1111/liv.70089
Relative Exchangeable Copper, Exchangeable Copper and Total Copper in the Diagnosis of Wilson Disease
Abstract
Background and aims: Diagnosing Wilson disease (WD) remains challenging. The exchangeable copper (CuEXC) methodology measures the non-ceruloplasmin-bound copper fraction in serum. Relative exchangeable copper (REC), the ratio of CuEXC to total serum copper (Total Cu), has been proposed as a potential diagnostic biomarker. This study aimed to evaluate the diagnostic performance of these three copper biomarkers in WD.
Methods: CuEXC and Total Cu levels were measured in newly diagnosed treatment-naïve patients with WD (n = 13), treated WD (n = 91), non-Wilsonian hepatic disease (n = 206) and non-Wilsonian acute liver failure (n = 22). REC, CuEXC and Total Cu were compared among groups. Receiver-operating characteristic analyses were performed.
Results: Median REC was significantly elevated among patients with WD compared to all other groups combined (23.6% vs. 4.9%, p < 0.001). The opposite was found for Total Cu (3.5 μmol/L vs. 17.2 μmol/L, p < 0.001). In newly diagnosed patients with WD, median REC was significantly higher than in treated patients (29.1% vs. 21.6%, p = 0.008). The optimal diagnostic cut-off value for REC was ≥ 13.8% (sensitivity 100% and specificity 99.6%) for newly diagnosed patients versus those with non-Wilsonian hepatic disease. For Total Cu, the optimal cut-off was ≤ 7.1 μmol/L (sensitivity 61.5% and specificity 99.1%) for newly diagnosed patients with WD versus those with non-Wilsonian hepatic disease.
Conclusion: Our data support the diagnostic value of REC in WD. The more broadly available Total Cu also demonstrates a strong diagnostic performance and may be useful in initial work-up. We suggest including REC and/or Total Cu in a future revision of the Leipzig score.
Keywords: Wilson disease; biomarker; diagnosis; non‐ceruloplasmin‐bound copper; relative exchangeable copper; total copper.
© 2025 The Author(s). Liver International published by John Wiley & Sons Ltd.
Conflict of interest statement
Z.M.: Speaker fees from Orphalan, Gilead; consultancy fees from Orphalan, Alexion, DeepGenomics and Prime Medicine (grants from Gilead). The other authors have no conflicts of interest to declare.
Figures
References
-
- Hellman N. E. and Gitlin J. D., “Ceruloplasmin Metabolism and Function,” Annual Review of Nutrition 22 (2002): 439–458. - PubMed
-
- Hung I. H., Suzuki M., Yamaguchi Y., Yuan D. S., Klausner R. D., and Gitlin J. D., “Biochemical Characterization of the Wilson Disease Protein and Functional Expression in the Yeast Saccharomyces cerevisiae ,” Journal of Biological Chemistry 272, no. 34 (1997): 21461–21466. - PubMed
-
- Kerkar N. and Roberts E. A., Clinical and Translational Perspectives on Wilson Disease (Academic Press, an imprint of Elsevier, 2019).
-
- Ala A., Walker A. P., Ashkan K., Dooley J. S., and Schilsky M. L., “Wilson's Disease,” Lancet 369, no. 9559 (2007): 397–408. - PubMed
MeSH terms
Substances
Grants and funding
- Anna Soria received support by a Río Hortega grant and Instituto de Salud Carlos III (ISCIII), Accion Estrategica en Salud (expedient CM23/00133).
- CERCA Programme/Generalitat de Catalunya
- European Union (expedient CM23/00133), Instituto de Salud Carlos III, Acción Estratégica en Salud, December 2023 Call (A.S.C)
- Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (Grant 2021_SGR_01322)
- Fabrikant Vilhelm Pedersen og Hustrus Legat
LinkOut - more resources
Full Text Sources
Medical
